Example: Heart Attack

Clinical Trials on Inclusion Body Myopathy 2

Total 16 results

NCT01417533

Recruiting

A Natural History Study of Patients With GNE Myopathy

Conditions: GNE Myopathy
NCT01517880

Completed

A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

Conditions: GNE Myopathy; Hereditary Inclusion Body Myopathy
NCT04009226

Recruiting

International GNE Myopathy Patient Registry

Conditions: GNE Myopathy; Hereditary Inclusion Body Myopathy
NCT04231266

Not yet recruiting

Multi-Center Study of ManNAc for GNE Myopathy

Conditions: GNE Myopathy
NCT02346461

Completed

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Conditions: GNE Myopathy
NCT01634750

Completed

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

Conditions: Hereditary Inclusion Body Myopathy (HIBM); GNE Myopathy
NCT00195637

Completed

Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy

Conditions: Hereditary Inclusion Body Myopathy
NCT01359319

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Conditions: Hereditary Inclusion Body Myopathy (HIBM)
NCT01830972

Completed

An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy

Conditions: GNE Myopathy; Hereditary Inclusion Body Myopathy (HIBM)
NCT02377921

Completed

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Conditions: Hereditary Inclusion Body Myopathy; Distal Myopathy With Rimmed Vacuoles; Distal Myopathy, Nonaka Type; GNE Myopathy
NCT02731690

Terminated

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Conditions: Hereditary Inclusion Body Myopathy; Distal Myopathy With Rimmed Vacuoles; Distal Myopathy, Nonaka Type; GNE Myopathy; Quadriceps Sparing Myopathy; Inclusion Body Myopathy 2
NCT01236898

Completed

Pharmacokinetic Study on N-acetylneuraminic Acid

Conditions: Nonaka Myopathy; Hereditary Inclusion Body Myopathy
NCT01784679

Completed

GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

Conditions: Hereditary Inclusion Body Myopathy; GNE Myopathy; Nonaka Disease; Quadriceps Sparing Myopathy (QSM); Distal Myopathy With Rimmed Vacuoles (DMRV)
NCT02736188

Terminated

Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Conditions: Hereditary Inclusion Body Myopathy; Distal Myopathy With Rimmed Vacuoles; Distal Myopathy, Nonaka Type; GNE Myopathy; Quadriceps Sparing Myopathy
NCT01902940

Completed

Natural History in CCFDN and IBM Syndromes

Conditions: Inclusion Body Myositis, Sporadic; Inclusion Body Myopathy, Autosomal-recessive; Inclusion Body Myopathy, Autosomal-dominant; Congenital Cataracts, Facial Dysmorphism, And Neuropathy
NCT02196909

Completed

Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)

Conditions: HIBM